Cargando…
A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis
Background: Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Objectives: Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy....
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484448/ https://www.ncbi.nlm.nih.gov/pubmed/29862855 http://dx.doi.org/10.1080/09546634.2018.1484875 |
_version_ | 1783414117442256896 |
---|---|
author | Hughes, M. Moore, T. Manning, J. Wilkinson, J. Watson, S. Samraj, P. Dinsdale, G. Roberts, C. Rhodes, L. E. Herrick, A. L. Murray, A. |
author_facet | Hughes, M. Moore, T. Manning, J. Wilkinson, J. Watson, S. Samraj, P. Dinsdale, G. Roberts, C. Rhodes, L. E. Herrick, A. L. Murray, A. |
author_sort | Hughes, M. |
collection | PubMed |
description | Background: Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Objectives: Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy. Methods: A custom-built device comprising infrared (850 nm), red (660 nm), and violet (405 nm) LEDs was utilized. DUs were irradiated with 10 J/cm(2) twice weekly for 3 weeks, with follow-up at weeks 4 and 8. Any safety concerns were documented. Patient opinion on time to deliver, feasibility, and pain visual analogue score (VAS; 0–100, 100 most severe) was collected. Patient and clinician DU global assessment VAS were documented. DUs were evaluated by laser Doppler perfusion imaging pre- and post-irradiation. Results: In all, 14 DUs in eight patients received a total of 46 light exposures, with no safety concerns. All patients considered LTTT ‘took just the right amount of time’ and was ‘feasible’, with a low associated mean pain VAS of 1.6 (SD: 5.2). Patient and clinician global DC VAS improved during the study (mean change: –7.1 and –5.2, respectively, both p < .001). DU perfusion significantly increased post-irradiation. Conclusions: LTTT for DUs is safe, feasible, and well tolerated. There was an early tentative suggestion of treatment efficacy. |
format | Online Article Text |
id | pubmed-6484448 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-64844482019-05-10 A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis Hughes, M. Moore, T. Manning, J. Wilkinson, J. Watson, S. Samraj, P. Dinsdale, G. Roberts, C. Rhodes, L. E. Herrick, A. L. Murray, A. J Dermatolog Treat Complex Medical Dermatology Background: Locally acting, well-tolerated treatments for systemic sclerosis (SSc) digital ulcers (DUs) are needed. Objectives: Our primary aim was to investigate the safety, feasibility, and tolerability of a novel low-level light therapy (LTTT). A secondary aim was to tentatively assess efficacy. Methods: A custom-built device comprising infrared (850 nm), red (660 nm), and violet (405 nm) LEDs was utilized. DUs were irradiated with 10 J/cm(2) twice weekly for 3 weeks, with follow-up at weeks 4 and 8. Any safety concerns were documented. Patient opinion on time to deliver, feasibility, and pain visual analogue score (VAS; 0–100, 100 most severe) was collected. Patient and clinician DU global assessment VAS were documented. DUs were evaluated by laser Doppler perfusion imaging pre- and post-irradiation. Results: In all, 14 DUs in eight patients received a total of 46 light exposures, with no safety concerns. All patients considered LTTT ‘took just the right amount of time’ and was ‘feasible’, with a low associated mean pain VAS of 1.6 (SD: 5.2). Patient and clinician global DC VAS improved during the study (mean change: –7.1 and –5.2, respectively, both p < .001). DU perfusion significantly increased post-irradiation. Conclusions: LTTT for DUs is safe, feasible, and well tolerated. There was an early tentative suggestion of treatment efficacy. Taylor & Francis 2018-07-31 /pmc/articles/PMC6484448/ /pubmed/29862855 http://dx.doi.org/10.1080/09546634.2018.1484875 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Complex Medical Dermatology Hughes, M. Moore, T. Manning, J. Wilkinson, J. Watson, S. Samraj, P. Dinsdale, G. Roberts, C. Rhodes, L. E. Herrick, A. L. Murray, A. A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis |
title | A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis |
title_full | A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis |
title_fullStr | A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis |
title_full_unstemmed | A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis |
title_short | A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis |
title_sort | feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis |
topic | Complex Medical Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484448/ https://www.ncbi.nlm.nih.gov/pubmed/29862855 http://dx.doi.org/10.1080/09546634.2018.1484875 |
work_keys_str_mv | AT hughesm afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT mooret afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT manningj afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT wilkinsonj afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT watsons afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT samrajp afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT dinsdaleg afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT robertsc afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT rhodesle afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT herrickal afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT murraya afeasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT hughesm feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT mooret feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT manningj feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT wilkinsonj feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT watsons feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT samrajp feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT dinsdaleg feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT robertsc feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT rhodesle feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT herrickal feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis AT murraya feasibilitystudyofanovellowlevellighttherapyfordigitalulcersinsystemicsclerosis |